Institutional members access full text with Ovid®

Share this article on:

Eccrine Syringofibroadenoma in Association With Acquired Epidermodysplasia Verruciformis

Tan, Timothy DO*; Guitart, Joan MD†,‡; Liu, Luzheng Lisa MD, PhD§; Brieva, Joaquin C. MD†; Amin, Sapna MD†; Rani, Monica MD¶; Gerami, Pedram MD†,‡; Yazdan, Pedram MD†

American Journal of Dermatopathology: July 2017 - Volume 39 - Issue 7 - p 534–537
doi: 10.1097/DAD.0000000000000816
Extraordinary Case Report

Abstract: A 75-year-old man with human immunodeficiency virus infection and numerous biopsy-proven warts for 10 years, refractory to cryosurgery, cimetidine, and topical imiquimod, presented with numerous pink to hypopigmented verrucous papules and plaques involving the face, trunk, buttocks, and groin. Laboratory evaluation revealed a CD4 T-cell count of 62 cells per microliter and human immunodeficiency virus viral load of <117 copies per milliliter. Biopsy of a plaque groin lesion was performed. Histopathology revealed vertically oriented anastomosing strands of basaloid epithelium arising from multiple points along the epidermis in a background fibrovascular stroma. Ductal differentiation was identified. Areas of epidermis showed compact orthokeratosis, coarse hypergranulosis, and keratinocytes with abundant steel-blue–gray cytoplasm, indicative of viral cytopathic changes. Cytologic atypia was not identified. Human papillomavirus (HPV) genotyping of this lesion was positive for types 5 and 14. Overall, the findings were consistent with epidermodysplasia verruciformis in association with eccrine syringofibroadenoma (ESFA). The patient was subsequently treated with acitretin and showed clinical improvement. ESFA is an uncommon benign adnexal tumor with unknown pathogenesis. Although its association with HPV has rarely been reported, ESFA in the setting of acquired epidermodysplasia verruciformis has not been described. The development of ESFA in this case may be the result of HPV-induced cellular transformation.

Departments of *Pathology, and

†Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL;

‡Robert H. Lurie Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL;

§Division of Dermatology, Department of Medicine, NorthShore University HealthSystem Vernon Hills, IL; and

¶Dermatology and Aesthetics of Wicker Park, Chicago, IL.

Reprints: Pedram Yazdan, MD, Department of Dermatology, Northwestern University, 676 North St. Clair Street, Suite 1600, Chicago, IL 60611 (e-mail: pyazdan@nm.org).

P. Gerami has served as a consultant to Myriad Genomics, DermTech Int, and Castle Biosciences and has received honoraria for this. J. Guitart has served as a consultant for Celgene, Actelion, and Genentech. The remaining authors declare no conflicts of interest.

Presented at The American Society of Dermatopathology, 53rd Annual Meeting; October 27, 2016; Chicago, IL.

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.